ao link
Who's Who Legal
Who's Who Legal
Menu
Thought Leaders

Thought Leaders

Thought Leader

WWL Ranking: Thought Leader
WWL Ranking: Thought Leader

Global Leader

WWL Ranking: Recommended

WWL says

Dieter Gericke is favoured by clients due to his “rare business and financial command”, combined with considerable knowledge of debt financing, private placement and US IPOs.

Biography

Dieter Gericke heads Homburger’s corporate and M&A team, as well as its China group, and is the former co-head of the capital markets practice. He has a law degree and a doctorate from the University of Zurich, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on public and private M&A, equity capital markets (including IPOs), private equity and corporate governance. He advises in shareholder activism corporate law, as well as securities regulations.

Recent assignments include the takeover of Syngenta by ChemChina; the sale of Therachon Pharma to Pfizer; the IPOs of ADC Therapeutics and Zur Rose Group; the share issuances by Santhera Pharmaceuticals and AC Immune; the acquisition of Haas Group by Bühler Group; the acquisition of Kunststoff Schwanden by Bregal; the takeover bid of Temenos to Fidessa; and the acquisition of Induchem by Givaudan. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke has authored various publications and chaired a number of panels, including those relating to public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA’s corporate/M&A and securities law committees.

Dieter Gericke is a board member of Gericke Group, which produces powder-processing equipment and systems for the food, pharmaceutical and chemical industries; and a former board member of Syngenta, a leading agrotechnology group.

WWL Ranking: Recommended
Healthcare 2021

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke is a transactional expert renowned for his considerable experience of high-value mergers and acquisitions in the healthcare sector.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the partial sale of the EF China business to Permira, the activist situation and capital increase of Meyer Burger Technology, the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International and Induchem by Givaudan, the IPO and financing of ADC Therapeutics and the IPO of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

WWL Ranking: Recommended

National Leader

WWL Ranking: Recommended

WWL says

Dieter Gericke is a top-notch lawyer, well versed in securities regulation and IPOs. 

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the partial sale of the EF China business to Permira, the activist situation and capital increase of Meyer Burger Technology, the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International and Induchem by Givaudan, the IPO and financing of ADC Therapeutics and the IPO of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

WWL Ranking: Recommended

WWL says

Dieter Gericke is an “excellent Swiss corporate lawyer” who brings “lots of practical experience” to his work on behalf of high-profile clients in the life sciences sector. 

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the partial sale of the EF China business to Permira, the activist situation and capital increase of Meyer Burger Technology, the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International and Induchem by Givaudan, the IPO and financing of ADC Therapeutics and the IPO of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

Switzerland - M&A 2021

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke draws praise for combining “profound expertise and comprehensive experience” with “great business acumen” and a “strong legal understanding”. 

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the partial sale of the EF China business to Permira, the activist situation and capital increase of Meyer Burger Technology, the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International and Induchem by Givaudan, the IPO and financing of ADC Therapeutics and the IPO of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

WWL Ranking: Recommended

WWL says

Dieter Gericke is a highly regarded corporate finance specialist who impresses peers with his expert handling of project financings and capital markets transactions.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the partial sale of the EF China business to Permira, the activist situation and capital increase of Meyer Burger Technology, the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International and Induchem by Givaudan, the IPO and financing of ADC Therapeutics and the IPO of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

Law Business Research
Law Business Research Ltd
Meridian House, 34-35 Farringdon Street
London EC4A 4HL, UK
© Law Business Research Ltd 1998-2021. All rights reserved.
Company No.: 03281866